US 11,938,146 B2
Treatment for coronavirus infection and associated cytokine toxicity
Sydney David Cullis-Hill, Bondi Junction (AU)
Filed by Sydney David Cullis-Hill, Bondi Junction (AU)
Filed on Nov. 30, 2022, as Appl. No. 18/071,800.
Application 18/071,800 is a continuation of application No. 17/910,220, previously published as PCT/AU2021/050215, filed on Mar. 12, 2021.
Claims priority of application No. 2020900751 (AU), filed on Mar. 12, 2020; and application No. 2020904824 (AU), filed on Dec. 23, 2020.
Prior Publication US 2023/0201250 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/737 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/737 (2013.01) [A61K 45/06 (2013.01); A61P 31/14 (2018.01)] 22 Claims
 
1. A method of treating coronavirus infection or a disease or condition caused by or associated with coronavirus infection, the method comprising:
providing an individual who is suspected of having or of having had a coronavirus infection,
administering to the individual, a therapeutically effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof
thereby treating or preventing coronavirus infection or a disease or condition caused by or associated with coronavirus infection in the individual.